Advertisement


Sean Khozin, MD, MPH, on Delivering Precision Cancer Care in the Era of Digital Medicine

SITC 2021

Advertisement

Sean Khozin, MD, MPH, of CancerLinQ, discusses the therapeutic advances that have made cancer care more targeted, even as real-world patient outcomes lag behind those reported in clinical trials. Dr. Khozin makes the case for the use of digital decision support tools to advance precision at the point of care.



Related Videos

Sarcoma
Immunotherapy

Emily Z. Keung, MD, on Interactions of Sarcoma, Immune Infiltrates, and Checkpoint Blockade

Emily Z. Keung, MD, of The University of Texas MD Anderson Cancer Center, discusses the complex interactions of immune infiltrates and neoadjuvant immune checkpoint blockade (ICB) in patients with resectable soft-tissue sarcoma. These interactions may hold the key to understanding pathologic response to ICB and ICB resistance (Abstract 379).

Lung Cancer
Immunotherapy

Stephanie T. Schmidt, PhD, on NSCLC: The Immunomodulatory Impact of Neoadjuvant Chemotherapy and Immune-Based Treatments

Stephanie T. Schmidt, PhD, of The University of Texas MD Anderson Cancer Center, discusses the first integrated examination of the immunomodulatory effects of neoadjuvant chemotherapy, nivolumab, and nivolumab plus chemotherapy in resected non–small cell lung cancer (Abstract 962).

Breast Cancer
Immunotherapy

Hans Wildiers, MD, on Metastatic Breast Cancer: Comparing Addition of Eftilagimod Alpha vs Placebo to Paclitaxel

Hans Wildiers, MD, of University Hospitals Leuven, discusses the final results from the phase IIb AIPAC study, which suggested that eftilagimod added to paclitaxel may be of benefit to patients older than 65 years with hormone receptor­–positive, HER2-negative metastatic breast cancer after endocrine-based therapy. Eftilagimod, which is a first-in-class antigen presenting cell activator, appeared to increase circulating CD4/CD8 T cells, which correlated to improved overall survival (Abstract 948).

Issues in Oncology

Lynda Chin, MD, on the Landscape and Future of Digital Medicine

Lynda Chin, MD, of the University of Texas, Austin Dell Medical School and Apricity Health, discusses precision medicine, barriers to its progress, and the challenges that must be met to facilitate better outcomes for patients. Building evidence and trust is key, Dr. Chin explains, as is developing an infrastructure that allows more clinicians to take part in the process.

Immunotherapy
Solid Tumors
Colorectal Cancer
Head and Neck Cancer

Mehmet Altan, MD, on Solid Tumors: Interim Safety and Efficacy Results on NKTR-255 Plus Cetuximab

Mehmet Altan, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from a phase Ib dose-escalation study, which showed early evidence of activity for NKTR-255, an investigational IL-15 receptor agonist, plus cetuximab in patients with solid tumors. Treatment appeared to lead to expansion and proliferation of NK and CD8+ cells (Abstract 957).

Advertisement

Advertisement



Advertisement